Skip to main content

NUEVAS APROXIMACIONES DE TERAPIA GENICA PARA LA DIABETES TIPO 2 Y LA OBESIDAD BASADAS EN LA ACTIVACION DEL TEJIDO ADIPOSO MARRON Y BROWNING DEL TEJIDO ADIPOSO BLANCO

SAF2014-54866-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CDK4 is an essential insulin effector in adipocytes

  • Lagarrigue, Sylviane
  • Lopez-Mejia, Isabel C.
  • Denechaud, Pierre Damien
  • Escoté, Xavier
  • Castillo-Armengol, Judit
  • Jimenez, Veronica|||0000-0001-9145-9877
  • Kahn, C. Ronald
  • Chavey, Carine
  • Giralt, Albert
  • Lai, Qiuwen
  • Zhang, Lianjun
  • Martinez-Carreres, Laia
  • Delacuisine, Brigitte
  • Annicotte, Jean Sébastien
  • Blanchet, Emilie
  • Huré, Sébastien
  • Abella, Anna
  • Tinahones, Francisco J.|||0000-0001-6871-4403
  • Vendrell, Joan|||0000-0002-6994-6115
  • Dubus, Pierre
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
  • Kahn, C. Ronald
  • Fajas, Lluís
Insulin resistance is a fundamental pathogenic factor that characterizes various metabolic disorders, including obesity and type 2 diabetes. Adipose tissue contributes to the development of obesity-related insulin resistance through increased release of fatty acids, altered adipokine secretion, and/or macrophage infiltration and cytokine release. Here, we aimed to analyze the participation of the cyclin-dependent kinase 4 (CDK4) in adipose tissue biology. We determined that white adipose tissue (WAT) from CDK4-deficient mice exhibits impaired lipogenesis and increased lipolysis. Conversely, lipolysis was decreased and lipogenesis was increased in mice expressing a mutant hyperactive form of CDK4 (CDK4R24C). A global kinome analysis of CDK4-deficient mice following insulin stimulation revealed that insulin signaling is impaired in these animals. We determined that insulin activates the CCND3-CDK4 complex, which in turn phosphorylates insulin receptor substrate 2 (IRS2) at serine 388, thereby creating a positive feedback loop that maintains adipocyte insulin signaling. Furthermore, we found that CCND3 expression and IRS2 serine 388 phosphorylation are increased in human obese subjects. Together, our results demonstrate that CDK4 is a major regulator of insulin signaling in WAT.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)

  • Motas, Sandra|||0000-0003-2748-5952
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Garcia, Miquel|||0000-0002-1602-4993
  • Marcó, Sara|||0000-0003-3502-5198
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Roca Lecha, Carles|||0000-0002-3744-3089
  • Sanchez Moreno, Xavier|||0000-0003-0897-0661
  • Sánchez Clares, Víctor|||0000-0001-8631-9239
  • Molas, Maria
  • Bertolín Gálvez, Joan|||0000-0002-5196-0955
  • Maggioni, Luca
  • León, Xavier|||0000-0002-8393-2721
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Mucopolysaccharidosis type II (MPSII) is an X-linked lysosomal storage disease characterized by severe neurologic and somatic disease caused by deficiency of iduronate-2-sulfatase (IDS), an enzyme that catabolizes the glycosaminoglycans heparan and dermatan sulphate. Intravenous enzyme replacement therapy (ERT) currently constitutes the only approved therapeutic option for MPSII. However, the inability of recombinant IDS to efficiently cross the blood-brain barrier (BBB) limits ERT efficacy in treating neurological symptoms. Here, we report a gene therapy approach for MPSII through direct delivery of vectors to the CNS. Through a minimally invasive procedure, we administered adeno-associated virus vectors encoding IDS (AAV9-Ids) to the cerebrospinal fluid of MPSII mice with already established disease. Treated mice showed a significant increase in IDS activity throughout the encephalon, with full resolution of lysosomal storage lesions, reversal of lysosomal dysfunction, normalization of brain transcriptomic signature, and disappearance of neuroinflammation. Moreover, our vector also transduced the liver, providing a peripheral source of therapeutic protein that corrected storage pathology in visceral organs, with evidence of cross-correction of nontransduced organs by circulating enzyme. Importantly, AAV9-Ids-treated MPSII mice showed normalization of behavioral deficits and considerably prolonged survival. These results provide a strong proof of concept for the clinical translation of our approach for the treatment of Hunter syndrome patients with cognitive impairment.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

In Vivo Gene Therapy for Mucopolysaccharidosis Type III (Sanfilippo Syndrome): A New Treatment Horizon

  • Marcó, Sara|||0000-0003-3502-5198
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
For most lysosomal storage diseases (LSDs), there is no cure. Gene therapy is an attractive tool for treatment of LSDs caused by deficiencies in secretable lysosomal enzymes, in which neither full restoration of normal enzymatic activity nor transduction of all cells of the affected organ is necessary. However, some LSDs, such as mucopolysaccharidosis type III (MPSIII) diseases or Sanfilippo syndrome, represent a difficult challenge because patients suffer severe neurodegeneration with mild somatic alterations. The disease's main target is the central nervous system (CNS) and enzymes do not efficiently cross the blood-brain barrier (BBB) even if present at very high concentration in circulation. No specific treatment has been approved for MPSIII. In this study, we discuss the adeno-associated virus (AAV) vector-mediated gene transfer strategies currently being developed for MPSIII disease. These strategies rely on local delivery of AAV vectors to the CNS either through direct intraparenchymal injection at several sites or through delivery to the cerebrospinal fluid (CSF), which bathes the whole CNS, or exploit the properties of certain AAV serotypes capable of crossing the BBB upon systemic administration. Although studies in small and large animal models of MPSIII diseases have provided evidence supporting the efficacy and safety of all these strategies, there are considerable differences between the different routes of administration in terms of procedure-associated risks, vector dose requirements, sensitivity to the effect of circulating neutralizing antibodies that block AAV transduction, and potential toxicity. Ongoing clinical studies should shed light on which gene transfer strategy leads to highest clinical benefits while minimizing risks. The development of all these strategies opens a new horizon for treatment of not only MPSIII and other LSDs but also of a wide range of neurological diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

2 sustains thermogenesis via Akt-induced glucose uptake and glycolysis in brown adipose tissue

  • Albert, Verena
  • Svensson, Kristoffer
  • Shimobayashi, Mitsugu
  • Colombi, Marco
  • Muñoz-Martínez, S|||0000-0003-0663-0575
  • Jimenez, Veronica|||0000-0001-9145-9877
  • Handschin, Christoph
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
  • Hall, Michael N.|||0000-0002-2998-0757
Activation of non-shivering thermogenesis () in brown adipose tissue () has been proposed as an anti-obesity treatment. Moreover, cold-induced glucose uptake could normalize blood glucose levels in insulin-resistant patients. It is therefore important to identify novel regulators of and cold-induced glucose uptake. Mammalian target of rapamycin complex 2 (2) mediates insulin-stimulated glucose uptake in metabolic tissues, but its role in is unknown. We show that 2 is activated in brown adipocytes upon β-adrenergic stimulation. Furthermore, mice lacking 2 specifically in adipose tissue (AdRi mice) are hypothermic, display increased sensitivity to cold, and show impaired cold-induced glucose uptake and glycolysis. Restoration of glucose uptake in by overexpression of hexokinase or activated Akt2 was sufficient to increase body temperature and improve cold tolerance in AdRi mice. Thus, 2 in mediates temperature homeostasis via regulation of cold-induced glucose uptake. Our findings demonstrate the importance of glucose metabolism in temperature regulation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Progressive neurologic and somatic disease in a novel mouse model of human mucopolysaccharidosis type IIIC

  • Marcó, Sara|||0000-0003-3502-5198
  • Pujol i Altarriba, Anna|||0000-0002-3484-598X
  • Roca Lecha, Carles|||0000-0002-3744-3089
  • Motas, Sandra|||0000-0003-2748-5952
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Garcia, Miquel|||0000-0002-1602-4993
  • Molas, Maria
  • Villacampa, Pilar|||0000-0002-2860-7475
  • Melia, Cristian S.
  • Sánchez Clares, Víctor|||0000-0001-8631-9239
  • Sanchez Moreno, Xavier|||0000-0003-0897-0661
  • Bertolín Gálvez, Joan|||0000-0002-5196-0955
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Mucopolysaccharidosis type IIIC (MPSIIIC) is a severe lysosomal storage disease caused by deficiency in activity of the transmembrane enzyme heparan-α-glucosaminide N-acetyltransferase (HGSNAT) that catalyses the N-acetylation of α-glucosamine residues of heparan sulfate. Enzyme deficiency causes abnormal substrate accumulation in lysosomes, leading to progressive and severe neurodegeneration, somatic pathology and early death. There is no cure for MPSIIIC, and development of new therapies is challenging because of the unfeasibility of cross-correction. In this study, we generated a new mouse model of MPSIIIC by targeted disruption of the Hgsnat gene. Successful targeting left LacZ expression under control of the Hgsnat promoter, allowing investigation into sites of endogenous expression, which was particularly prominent in the CNS, but was also detectable in peripheral organs. Signs of CNS storage pathology, including glycosaminoglycan accumulation, lysosomal distension, lysosomal dysfunction and neuroinflammation were detected in 2-month-old animals and progressed with age. Glycosaminoglycan accumulation and ultrastructural changes were also observed in most somatic organs, but lysosomal pathology seemed most severe in liver. Furthermore, HGSNAT-deficient mice had altered locomotor and exploratory activity and shortened lifespan. Hence, this animal model recapitulates human MPSIIIC and provides a useful tool for the study of disease physiopathology and the development of new therapeutic approaches. Summary: A new animal model of the severe neurodegenerative lysosomal disorder mucopolysaccharidosis IIIC recapitulates the human disease, with progressive CNS and somatic lysosomal pathology, and shortened lifespan.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bone Morphogenetic Protein 4 Gene Therapy in Mice Inhibits Myeloma Tumor Growth, But Has a Negative Impact on Bone

  • Westhrin, Marita
  • Holien, Toril|||0000-0002-2051-5824
  • Zahoor, Muhammad
  • Moen, Siv Helen
  • Buene, Glenn
  • Størdal, Berit
  • Hella, Hanne
  • Yuan, Huipin
  • de Bruijn, Joost D.
  • Martens, Anton
  • Groen, Richard W. J.
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
  • Smith, Ulf|||0000-0002-1439-4608
  • Sponaas, Anne-Marit
  • Sundan, Anders
  • Standal, Therese|||0000-0003-3314-8522
Multiple myeloma is characterized by accumulation of malignant plasma cells in the bone marrow. Most patients suffer from an osteolytic bone disease, caused by increased bone degradation and reduced bone formation. Bone morphogenetic protein 4 (BMP4) is important for both pre- and postnatal bone formation and induces growth arrest and apoptosis of myeloma cells. BMP4-treatment of myeloma patients could have the potential to reduce tumor growth and restore bone formation. We therefore explored BMP4 gene therapy in a human-mouse model of multiple myeloma where humanized bone scaffolds were implanted subcutaneously in RAG2 -/- γC -/- mice. Mice were treated with adeno-associated virus serotype 8 BMP4 vectors (AAV8-BMP4) to express BMP4 in the liver. When mature BMP4 was detectable in the circulation, myeloma cells were injected into the scaffolds and tumor growth was examined by weekly imaging. Strikingly, the tumor burden was reduced in AAV8-BMP4 mice compared with the AAV8-CTRL mice, suggesting that increased circulating BMP4 reduced tumor growth. BMP4-treatment also prevented bone loss in the scaffolds, most likely due to reduced tumor load. To delineate the effects of BMP4 overexpression on bone per se, without direct influence from cancer cells, we examined the unaffected, non-myeloma femurs by μCT. Surprisingly, the AAV8-BMP4 mice had significantly reduced trabecular bone volume, trabecular numbers, as well as significantly increased trabecular separation compared with the AAV8-CTRL mice. There was no difference in cortical bone parameters between the two groups. Taken together, BMP4 gene therapy inhibited myeloma tumor growth, but also reduced the amount of trabecular bone in mice. Our data suggest that care should be taken when considering using BMP4 as a therapeutic agent. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

BMP7 overexpression in adipose tissue induces white adipogenesis and improves insulin sensitivity in ob/ob mice

  • Casaña Lorente, Estefania|||0000-0002-1353-5018
  • Jimenez, Veronica|||0000-0001-9145-9877
  • Sacristan, Victor|||0000-0003-0356-0356
  • Muñoz-Martínez, S|||0000-0003-0663-0575
  • Jambrina Pallarés, Claudia
  • Rodó Morera, Jordi|||0000-0001-8533-2597
  • Garcia, Miquel|||0000-0002-1602-4993
  • Mallol, Cristina|||0000-0002-2920-9612
  • León, Xavier|||0000-0002-8393-2721
  • Franckhauser, Sylvie|||0000-0001-5255-1224
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Background/objectives: During obesity, hypertrophic enlargement of white adipose tissue (WAT) promotes ectopic lipid deposition and development of insulin resistance. In contrast, WAT hyperplasia is associated with preservation of insulin sensitivity. The complex network of factors that regulates white adipogenesis is not fully understood. Bone morphogenic protein 7 (BMP7) can induce brown adipogenesis, but its role on white adipogenesis remains to be elucidated. Here, we assessed BMP7-mediated effects on white adipogenesis in ob/ob mice. Methods: BMP7 was overexpressed in either WAT or liver of ob/ob mice using adeno-associated viral (AAV) vectors. Analysis of gene expression, histological and morphometric alterations, and metabolites and hormones concentrations were carried out. Results: Overexpression of BMP7 in adipocytes of subcutaneous and visceral WAT increased fat mass, the proportion of small-size adipocytes and the expression of adipogenic and mature adipocyte genes, suggesting induction of adipogenesis irrespective of fat depot. These changes were associated with reduced hepatic steatosis and improved insulin sensitivity. In contrast, liver-specific overproduction of BMP7 did not promote WAT hyperplasia despite BMP7 circulating levels were similar to those achieved after genetic engineering of WAT. Conclusions: This study unravels a new autocrine/paracrine role of BMP7 on white adipogenesis and highlights that BMP7 may modulate WAT plasticity and increase insulin sensitivity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

FGF21 gene therapy as treatment for obesity and insulin resistance

  • Jimenez, Veronica|||0000-0001-9145-9877
  • Jambrina Pallarés, Claudia|||0000-0002-9093-5568
  • Casaña Lorente, Estefania|||0000-0002-1353-5018
  • Sacristan, Victor|||0000-0003-0356-0356
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Darriba, Sara
  • Rodó Morera, Jordi|||0000-0001-8533-2597
  • Mallol, Cristina|||0000-0002-2920-9612
  • Garcia, Miquel|||0000-0002-1602-4993
  • León, Xavier|||0000-0002-8393-2721
  • Marcó, Sara|||0000-0003-3502-5198
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Elias Puigdomenech, Ivet|||0000-0002-1304-9597
  • Casellas Comallonga, Alba|||0000-0003-0203-4733
  • Grass Costa, Ignasi|||0000-0002-6917-3271
  • Elias Bosch, Gemma|||0000-0003-1985-7955
  • Ferre, Tura|||0000-0001-9713-0829
  • Motas, Sandra|||0000-0003-2748-5952
  • Franckhauser, Sylvie|||0000-0001-5255-1224
  • Mulero, Francisca|||0000-0001-9584-4211
  • Navarro Beltrán, Marc|||0000-0002-9678-6129
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Prevalence of type 2 diabetes (T2D) and obesity is increasing worldwide. Currently available therapies are not suited for all patients in the heterogeneous obese/T2D population, hence the need for novel treatments. Fibroblast growth factor 21 (21) is considered a promising therapeutic agent for T2D/obesity. Native 21 has, however, poor pharmacokinetic properties, making gene therapy an attractive strategy to achieve sustained circulating levels of this protein. Here, adeno-associated viral vectors () were used to genetically engineer liver, adipose tissue, or skeletal muscle to secrete 21. Treatment of animals under long-term high-fat diet feeding or of ob/ob mice resulted in marked reductions in body weight, adipose tissue hypertrophy and inflammation, hepatic steatosis, inflammation and fibrosis, and insulin resistance for.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Identification of miRNAs Involved in Reprogramming Acinar Cells into Insulin Producing Cells

  • Teichenne, Joan|||0000-0002-3455-5923
  • Morró Larrubia, Meritxell|||0000-0003-1725-9599
  • Casellas, Alba|||0000-0003-0203-4733
  • Jimenez, Veronica|||0000-0001-9145-9877
  • Tellez, Noelia
  • Leger, Adrien
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
  • Ayuso, Eduard|||0000-0003-0811-2229
Reprogramming acinar cells into insulin producing cells using adenoviral (Ad)-mediated delivery of Pdx1, Ngn3 and MafA (PNM) is an innovative approach for the treatment of diabetes. Here, we aimed to investigate the molecular mechanisms involved in this process and in particular, the role of microRNAs. To this end, we performed a comparative study of acinar-to-β cell reprogramming efficiency in the rat acinar cell line AR42J and its subclone B13 after transduction with Ad-PNM. B13 cells were more efficiently reprogrammed than AR42J cells, which was demonstrated by a strong activation of β cell markers (Ins1, Ins2, IAPP, NeuroD1 and Pax4). miRNome panels were used to analyze differentially expressed miRNAs in acinar cells under four experimental conditions (i) non-transduced AR42J cells, (ii) non-transduced B13 cells, (iii) B13 cells transduced with Ad-GFP vectors and (iv) B13 cells transduced with Ad-PNM vectors. A total of 59 miRNAs were found to be differentially expressed between non-transduced AR42J and B13 cells. Specifically, the miR-200 family was completely repressed in B13 cells, suggesting that these cells exist in a less differentiated state than AR42J cells and as a consequence they present a greater plasticity. Adenoviral transduction per se induced dedifferentiation of acinar cells and 11 miRNAs were putatively involved in this process, whereas 8 miRNAs were found to be associated with PNM expression. Of note, Ad-PNM reprogrammed B13 cells presented the same levels of miR-137-3p, miR-135a-5p, miR-204-5p and miR-210-3p of those detected in islets, highlighting their role in the process. In conclusion, this study led to the identification of miRNAs that might be of compelling importance to improve acinar-to-β cell conversion for the future treatment of diabetes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Integrated gene expression profiles reveal a transcriptomic network underlying the thermogenic response in adipose tissue

  • Rodó Morera, Jordi|||0000-0001-8533-2597
  • Garcia, Miquel|||0000-0002-1602-4993
  • Casaña Lorente, Estefania|||0000-0002-1353-5018
  • Muñoz-Martínez, S|||0000-0003-0663-0575
  • Jambrina Pallarés, Claudia
  • Sacristan, Victor|||0000-0003-0356-0356
  • Franckhauser, Sylvie|||0000-0001-5255-1224
  • Grass Costa, Ignasi|||0000-0002-6917-3271
  • Jimenez, Veronica|||0000-0001-9145-9877
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Obesity and type 2 diabetes are two closely related diseases representing a serious threat worldwide. An increase in metabolic rate through enhancement of non-shivering thermogenesis in adipose tissue may represent a potential therapeutic strategy. Nevertheless, a better understanding of thermogenesis transcriptional regulation is needed to allow the development of new effective treatments. Here, we aimed to characterize the specific transcriptomic response of white and brown adipose tissues after thermogenic induction. Using cold exposure to induce thermogenesis in mice, we identified mRNAs and miRNAs that were differentially expressed in several adipose depots. In addition, integration of transcriptomic data in regulatory networks of miRNAs and transcription factors allowed the identification of key nodes likely controlling metabolism and immune response. Moreover, we identified the putative role of the transcription factor PU.1 in the regulation of PPARγ-mediated thermogenic response of subcutaneous white adipose tissue. Therefore, the present study provides new insights into the molecular mechanisms that regulate non-shivering thermogenesis.